Related Experiment Video
Updated: Aug 2, 2026

Efficient iPS Cell Generation from Blood Using Episomes and HDAC Inhibitors
Published on: October 28, 2014
Therapeutic mammalian artificial episomal chromosomes
1Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, 27599-7295, USA. vos@med.unc.edu
Mammalian artificial chromosomes (MACs) are engineered using two main strategies for gene therapy. These methods offer distinct advantages for therapeutic vector development and creating transgenic animals.
Area of Science:
- Biotechnology
- Molecular Biology
- Gene Therapy
Background:
- Mammalian artificial chromosomes (MACs) are being developed as advanced therapeutic vectors.
- Two primary strategies exist: in vitro cloning and in situ assembly.
- Current MAC systems primarily use viral or genomic cis-elements.
Purpose of the Study:
- To explore engineering strategies for mammalian artificial chromosomes (MACs).
- To discuss the potential of MACs in gene therapy and transgenic animal production.
- To highlight the promise of chimeric MAC systems.
Main Methods:
- In vitro MAC cloning involves enzymatic ligation and propagation in single-cell organisms.
- In situ MAC assembly uses mammalian cells as 'foster' donors for MAC element integration.
- Chimeric MAC systems may combine viral and genomic cis-elements.
Main Results:
- In vitro MACs are suitable for somatic gene therapy due to their compactness.
- In situ MACs offer long-term persistence for generating therapeutic gene-expressing transgenic animals.
- The herpes viral oriP/EBNA1 system exemplifies a self-replicating episome with therapeutic potential.
Conclusions:
- Both in vitro and in situ MAC engineering strategies have unique applications in biotechnology.
- Next-generation MACs will likely incorporate chimeric cis-elements for enhanced flexibility.
- The oriP/EBNA1 system showcases the potential of engineered episomes for future therapeutic uses.
More Related Videos
09:46Isolation, Culture, and Genetic Engineering of Mammalian Primary Pigment Epithelial Cells for Non-Viral Gene Therapy
Published on: February 26, 2021
09:56Epigenetic Engineering of K562 Cells: Dual-Vector Episomal Strategy for Stable Targeted DNA Methylation using dCas9-DNMT3A and -HDAC1 Fusion Proteins
Published on: October 31, 2025
Related Concept Videos
In-vitro Mutagenesis
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...